Have you been diagnosed with cancer. If so, you may be able to take part in a research study looking to improve cancer care for patients whose treatment outcomes have led to challenges in their quality of life.
Are you a patient with advanced basal-like pancreatic adenocarcinoma? If so this could the a Trial for you to as this is a Phase I/II trial is to evaluate the safety, efficacy and tolerability of low-dose EGFR inhibitors in combination with bi-weekly gemcitabine/nab-paclitaxel (GnP) in subjects with basal tumors
The purpose of this study is to test the safety and effectiveness of the test drug IMGN151-1001 on your cancer.
Have you been diagnosed with relapsed or refractory light chain amyloidosis? If so, you may be able to take part in a research study looking at the safety and tolerability of giving Venetoclax, MLN9708 (ixazomib citrate) and Dexamethasone to patients with relapsed or refractory light chain amyloidosis.
Do you have kidney or bladder cancer. You may be able to participate in a research study to find out if the investigational drug REGN10597 is safe, tolerable, and effective in treating kidney and bladder cancer.
Do you have bladder cancer that has spread to nearby tissue or other parts of the body? You may be able to participate in a research study to find out if the investigational drug disitamab vedotin alone or with pembrolizumab works to treat bladder cancer.
Do you have bladder cancer and have had your bladder removed? If so, you may be able to take part in a research study to determine if patients need additional treatment called immunotherapy to prevent cancer from coming back.
In this study, we want to see if a new type of medicine for lung cancer treatment is better than the usual treatments. We are curious if this new medicine could improve things for people with lung cancer. This will help us understand if the new medicine will treat people better or faster.
Have you been diagnosed with pancreatic adenocarcinoma? If so, you may be a good fit to help us learn if combination treatment with specific drugs may stimulate the body's immune system against cancer cells.
Have you been diagnosed with Multiple Myeloma? Have you received idecabtagene vicleucel (ide-cel (Abecma)) CAR-T treatment? If so, you may be able to take part in a research study looking at for how long a new drug called iberdomide will keep Multiple Myeloma under control (in remission).